Interferon-alpha inhibits airway eosinophilia and hyperresponsiveness in an animal asthma model

Yasuko Kikkawa, Kumiya Sugiyama*, Kazuki Obara, Hirokuni Hirata, Yasutsugu Fukushima, Masao Toda, and Takeshi Fukuda

Background: Asthma is characterized by a chronic inflammatory process involving high numbers of inflammatory cells and mediators which have multiple inflammatory effects on the airway. Interferon (IFN)-alpha, which is used widely for treating chronic hepatitis C, is reported to have an effect on patients with Churg-Strauss syndrome. Therefore, it may also be suitable for patients with severe asthma.

Objective: We studied the effect of IFN-alpha on airway eosinophilia in a guinea pig model of asthma and the expression of adhesion molecules on human eosinophils and vascular endothelial cells.

Methods: After antigen challenge, airway hyperresponsiveness and airway eosinophilia were measured in a guinea pig asthma model with or without airway IFN-alpha administration. Expression of adhesion molecules on eosinophils and cultured human umbilical vein endothelial cells (HUVECs) was also evaluated with or without IFN-alpha.

Results: IFN-alpha inhibited eosinophil recruitment into the tracheal wall and improved airway hyperresponsiveness in sensitized guinea pigs. IFN-alpha also significantly suppressed IL-1 beta-induced intercellular adhesion molecule-1 (ICAM-1) expression on HUVECs. However, IFN-alpha did not suppress platelet-activating factor-induced macrophage antigen-1 expression on human eosinophils. IFN-alpha significantly inhibited eosinophil adhesion to IL-1 beta-induced HUVECs and migration through IL-1 beta induced HUVECs.

Conclusion: The findings suggest that the modulation of ICAM-1 in lung with pre-existing inflammation following treatment with IFN-alpha may be a novel and selective treatment for control of chronic airway inflammation and hyperresponsiveness associated with asthma.

Key words: Adhesion molecule; Asthma; Eosinophil; Interferon-alpha; Intercellular adhesion molecule-1; Macrophage antigen-1

INTRODUCTION

Asthma is characterized as eosinophilic airway inflammation and hyperresponsiveness [1, 2]. T helper 2 (Th2) cytokines such as interleukin (IL)-5 activate eosinophils [3-7] and enhance eosinophil adhesion to vascular epithelial cells [8], and migration.

Correspondence: Kumiya Sugiyama
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, 880 Kita-kobayashi, Mibu, Tochigi 321-0293, Japan
Tel: +81-282-87-2151
Fax: +81-282-86-5080
E-mail: sugiyama@dokkyomed.ac.jp

Received: June 27, 2012
Accepted: October 22, 2012
http://apallergy.org

This is an Open Access article distributed under the terms of the Creative Commons Attribution. Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2012. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.
IFN-α inhibits airway hyperresponsiveness

of eosinophils causes eosinophilic airway inflammation.

Interferon (IFN)-alpha has been widely used in the treatment of chronic hepatitis C [9-12]. IFN-alpha also favors both induction of Th1 cytokines and suppression of Th2 cytokines by signaling mechanisms [13-15]. IFN-alpha inhibits the production of IL-5 by CD4+ T cells [16] and inhibits eosinophils and CD4+ T cell recruitment into tissue [17]. In fact, the efficacy of therapeutic administration of IFN-alpha to patients with Churg-Strauss syndrome has been reported [18-20]. Consequently, these findings suggest that IFN-alpha may downregulate eosinophil activation and have an effect on severe asthma. To evaluate the effect of IFN-alpha for asthma, a guinea pig model of asthma was used for airway hyperresponsiveness, and human vascular endothelial cells and human eosinophils were used for the expression of adhesion molecules. IFN-alpha could be a viable treatment if its efficacy for asthma can be demonstrated, because IFN-alpha has been used widely for the treatment of chronic hepatitis C and there is ample information on IFN-alpha, including its side effects.

MATERIALS AND METHODS

Animals
Female Hartley guinea pigs (250–300 g) were purchased from SLC (Shizuoka, Japan).

Reagents
Human IFN-alpha (Hayashihara Lab, Osaka, Japan) composed of subtypes alpha 2, alpha 7, and alpha 8 was used for in vitro and in vivo experiments. Recombinant human (rh) IL-1 beta (Genzyme Co., MA, USA) and platelet activating factor (PAF; Sigma-Aldrich Co., MO, USA) were also used.

Antibodies
Anti-macrophage antigen-1 (Mac-1; CD11b, and mouse IgG2a) monoclonal antibody (mAb) and mouse isotype control mAbs (IgG1 and IgG2a) were purchased from Becton-Dickinson (CA, USA). Anti-human intercellular adhesion molecule-1 (ICAM-1; mouse IgG1) mAb and anti-human vascular adhesion molecule-1 (VCAM-1; mouse IgG1) were purchased from Genzyme Co. Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse F(ab)’2 fragments were also purchased from Becton-Dickinson.

Sensitization
Guinea pigs were sensitized by exposure to aerosolized 10 mg/mL of ovalbumin (OVA; Sigma-Aldrich Co.) saline solution once a day for 10 consecutive days [21]. The aerosol was generated by an ultrasonic nebulizer (NE-IOB; Omuron Co., Ltd., Kyoto, Japan) applied to the center of a round tub. Guinea pigs were placed radially with their heads directed towards the aerosol-supplying center of the tub and were each exposed to an equivalent density of OVA aerosols for 10 min on each occasion. Seven days after the end of the 10-day exposure of OVA aerosols, and 3 h before the OVA challenge, the guinea pigs were intraperitoneally (IP) injected with IFN-alpha, which were suspended 2.0 mL/animal of (a) high- (2 × 10⁷ U/kg) or (b) low dose- (2 × 10⁶ U/kg) or (c) saline solution alone. Then, they were exposed to 10 mg/mL aerosolized OVA saline solution for 10 min using a DeVilbiss 646 nebulizer (DeVilbiss Co., PA, USA) driven by compressed air at 5 L/min. Airway hyperresponsiveness was measured immediately before and 24 h after OVA challenge (Fig. 1).

Measurement of airway hyperresponsiveness
Respiratory resistance (Rrs) was measured by a forced-oscillation technique (Mead’s oscillation method) [22]. These measurements were carried out in inhalation-sensitized guinea pigs [23]. Conscious animals were placed in a body plethysmograph, leaving their heads outside and their necks restrained by a doughnut-shaped rubber balloon which scaled the body chamber, and an 18 Hz sine-wave oscillation was applied to their body surfaces. Oscillating pressure was generated (RC oscillator ORC 11; Kikusui Electronics Co., Kanagawa, Japan) with a 24 cm wofer speaker (Pioneer Co., Kanagawa, Japan) derived by a sine-wave generator and power amplifier (M-50; NEC Co., Tokyo, Japan). A rubber mask

Fig. 1. Sensitization and challenge protocols.
with a 200 mesh screen was snugly applied to the face in order to measure the flow rate. The flow rate through the mask was measured by detecting the pressure difference across the 200 mesh screen using a differential pressure transducer (DP-45-18; Validyne Engineering Co., CA, USA). Box pressure was measured by a pressure transducer (DP-45-26; Validyne Engineering Co.). The signals of the flow rate and the box pressure were amplified (Carrier Amplifier; Shizume Medical Co., Tokyo, Japan) and were then recorded on a polygraph recorder (WTR 751; Graphtec Co., Kanagawa, Japan), as well as on the X and Y axis of an oscilloscope (COS5021TM; Kikusui Electronics Co.). Rs was calculated from the ratio of amplitude of the oscillating box pressure and flow rate fluctuations.

Airway responsiveness to inhaled histamine (Sigma-Aldrich Co.) was expressed using PC200-Rrs-histamine. Serially doubling dilutions of histamine solution of 39–20,000 µg/mL were prepared. Animals were exposed to the aerosol of each histamine solution for 10 min by increasing the concentration of each solution as described above. Rs was measured immediately after inhalation, which was stopped when Rs exceeded 200% of the baseline level. PC200-Rrs-histamine expressed the concentration of histamine solution to produce 100% increase in Rs compared with baseline.

Eosinophil count
Animals were killed by IP injection of pentobarbital (100 mg/kg body weight). Trachea were removed and fixed in 10% formalin and embedded in paraffin, and 3-µm-thick sections were stained with May-Giemsa and Hansel solution. Epithelial and under basement membrane eosinophils were counted separately. The above protocol, including sensitization and measurement of airway hyperresponsiveness, was approved by the Committee of Laboratory Animal Research Center at Dokkyo Medical University (No. GP-9832).

Isolation of human eosinophils
Human eosinophils were isolated by the technique described by Tenor et al. [24]. Purity of attained eosinophils was > 99.5%, as assessed by Kimura staining after this procedure.

Adhesion assay
Human umbilical vein endothelial cells (HUVECs; Kurabou Biomedical, Osaka, Japan) were grown to confluence in a 24-well plate (Becton-Dickinson, Lincoln Park, NJ), and purified human eosinophils (2 × 10⁶ cells/well) were added. Monolayers of HUVECs were pretreated with IFN-alpha or human albumin at 37°C in a humidified CO₂ (5%) incubator for 30 min and stimulated with 5 nM/mL of rh IL-1 beta for 4 h. After incubation, non-adherent eosinophils were collected, and the percentage of adhesion was calculated as follows: [(total cell number – non-adherent cell number)/total cell number] × 100.

Transendothelial migration assay
A Transendothelial migration assay was prepared using a modified version of Ebisawa’s method [25]. HUVECs at 2 × 10⁴ cells from the third passage were cultured on 2% gelatin-coated Transwell culture inserts (6.5-mm diameter polycarbonate membrane with 5-µm pores, Costar, MA, USA). Fresh endothelial cell growth medium (0.2 mL EB; Sankojunyaku, Tokyo, Japan) was added to the upper and lower transwell chambers. A monolayer of confluent HUVECs formed within 7 days. To confirm HUVEC confluency, monolayers were stained routinely with Diff-Quik (American Scientific Products, McGraw Park, IL) before experiments. After preincubation for 30 min with IFN-alpha, the HUVECs monolayer was incubated at 37°C for 4 h with 5 ng/mL of IL-1 beta or EBM only without glucocorticoid (control). After incubation, the culture medium with IFN-alpha and IL-1 beta was removed and rinsed twice. Then, 0.2 mg eosinophil suspension (2 × 10⁶ cells/mL) was added to each upper chamber and incubated for 2 h at 37°C. After incubation, non-adherent cells in the upper chamber were removed. Eosinophils that had migrated and fallen into the lower chamber were removed to centrifugal tubes and centrifuged at 300 g for 5 min at 4°C. Migrated eosinophils were stained with trypan blue and counted.

Stimulation of eosinophils and HUVECs
Eosinophils resuspended in RPMI-1640 supplemented with 1% fetal bovine serum at a cell concentration of 1 × 10⁶/mL were incubated for 30 min with IFN-alpha and added platelet-activating factor (PAF; 1 × 10⁻⁵ M/mL) for 15 min. HUVECs were detached from the culture flasks using 0.025% trypsin and 0.01% EDTA solution and were counted and resuspended at 1 × 10⁶ cells/mL in EBM without glucocorticoid. After preincubation for 30 min with IFN-alpha, HUVECs were incubated with 5 ng/mL of rh IL-1 beta for 4 h. Cells were then washed twice with phosphate buffered saline and kept on ice until analyzed.

Immunofluorescence
Eosinophils were evaluated by immunofluorescence and flow
cytometry for expression of CD11b, LFA-1a, and VLA4 before and after PAF stimulation. In addition, HUVECs were evaluated for expression of ICAM-1. Cells were labeled with saturating amounts of each mAb (~10–50 µL), and volume was made up to 100 µL where necessary with ice-cold flow cytometry buffer. After incubation for 30 min at 4°C, the cells were washed once with 2 mL of cold flow cytometry buffer, resuspended in PBS, and kept on ice until analyzed. When unlabeled mAbs were used, cells were mixed with an excess of FITC-conjugated F(ab')2 fragments of goat antibody to mouse immunoglobulins. After incubation for 15 min at 4°C, the cells were washed, resuspended in PBS, and kept on ice until analyzed.

**Flow cytometry**
Flow cytometry was performed on a FACScan instrument (Becton-Dickinson) equipped with an electronic (Coulter) volume sensor, which was standardized with fluorescent microbeads. The fluorescence intensity of 5,000 cells was determined from each sample by logarithmic amplification, which was converted to the linear equivalent by means of a Hewlett-Packard Consort 30 computer. Cell populations and debris were defined by gating the volume and 90° light scatter parameters. Dead cells were excluded from analysis by gating out propidium iodide-positive cells. The mean fluorescence of the population was calculated using the computer, and the value for the control antibody was subtracted from the value for the specific mAb to give a specific mean fluorescence value.

**Statistical analysis**
All statistical analyses were performed using Microsoft Excel®, StatView®, or JMP® for the t-test and Wilcoxon signed rank test. Differences with a p value < 0.05 were considered significant. Results are expressed as mean ± SEM values. PC200-Rrs-histamine values were converted into a logarithm for statistical calculation.

**RESULTS**

**Effect of IFN-alpha on OVA-induced eosinophil infiltration into the trachea and on airway hyperresponsiveness**
High- (2 × 10^7 U/kg) and low- (2 × 10^6 U/kg) dose IFN-alpha significantly inhibited eosinophil accumulation (1132 ± 70/mm² and 1305 ± 68/mm², respectively) compared with no treatment (1501 ± 64/mm²) (p < 0.01 and p < 0.05, respectively) (Fig. 2). Similarly, high- and low-dose IFN-alpha significantly decreased airway hyperresponsiveness (Rrs: 5000 ± 945 µg/mL histamine and Rrs: 1228 ± 365 µg/mL histamine, respectively) compared with no treatment (Rrs: 279 ± 68 µg/mL histamine) (p < 0.01, p < 0.05, respectively). High-dose IFN-alpha significantly decreased airway hyperresponsiveness compared with models before OVA challenge (1651 ± 325 µg/mL, respectively) (p < 0.05) (Fig. 3). Histological examination and measurement of airway hyperresponsiveness were performed separately, because histamine might induce airway inflammation.

**Effects of IFN-alpha on adhesion molecule expression on human eosinophils and HUVECs**
In vitro, IFN-alpha was suspended in culture medium at 1 × 10^5 U/mL (high-dose), 1 × 10^4 U/mL (middle-dose), or 1 × 10^3 U/mL (low-dose), and no treatment was used as a control. Mean fluorescence of ICAM-1 expression on HUVACs activated by 5 ng/mL of IL-1 beta was 221.7 ± 15.0, 237.8 ± 14.5, and 271.7 ± 28.7 for high-dose, middle-dose, low-dose pretreatment, respectively, compared with 279.3 ± 15.1 for no treatment (Fig. 4A). ICAM-
1 expression was inhibited dose-dependently by IFN-alpha ($p < 0.01$, $p < 0.05$). Mean fluorescence of VCAM-1 expression on HUVACs activated by 5 ng/mL of IL-1 beta was $189.0 \pm 29.7$, $266.9 \pm 23.0$, and $256.5 \pm 22.8$ for high-dose, middle-dose, low-dose pretreatment, respectively, compared with $283.4 \pm 30.9$ for no treatment (Fig. 4B). VCAM-1 expression was inhibited by high-dose IFN-alpha only ($p < 0.01$). However, IFN-alpha did not suppress PAF-induced Mac-1 expression on human eosinophils (data not shown).

Effects of IFN-alpha on eosinophil adhesion and transmigration through HUVECs

For the adhesion investigation, the percent of adherent eosinophils was $52.6 \pm 4.1\%$, $63.4 \pm 4.1\%$, and $71.6 \pm 4.1\%$ for high-dose, middle-dose, low-dose pretreatment, respectively, compared with $83.8 \pm 4.9\%$ for no treatment (Fig. 5). IFN-alpha significantly and dose dependently inhibited eosinophil adhesion to HUVECs activated by 5 ng/mL of IL-1 beta ($p < 0.01$). Furthermore, the percent of migrated eosinophils was $6.7 \pm 1.0\%$, $8.0 \pm 1.3\%$, and $8.5 \pm 1.4\%$ for high-dose, middle-dose, and low-dose pretreatment, respectively, compared with $10.3 \pm 1.3\%$ for no treatment (Fig. 6). High dose IFN-alpha significantly inhibited eosinophil migration through IL-1 beta-activated HUVECs compared with controls ($p < 0.02$).

DISCUSSION

We found that IFN-alpha inhibited both airway eosinophilia and hyperresponsiveness in a guinea pig model of asthma. IFN-alpha inhibited the expression of ICAM-1 on vascular endothelial...
IFN-α inhibits airway hyperresponsiveness

Several studies that evaluated the relationship between IFN-alpha and pulmonary function have been published and are in agreement with the present findings. For example, for severe corticosteroid-dependent asthma without chronic hepatitis C, IFN-alpha improved pulmonary function, including forced expiratory volume in 1 second (FEV1) and peak expiratory flow (PEF) [26-28]. On the other hand, patients with chronic hepatitis C did not show the same results. It was reported that two patients with both asthma and chronic hepatitis C experienced exacerbation of asthma promptly after the use of IFN-alpha [29]. In non-asthmatic patients with chronic hepatitis C, 3 of 17 experienced enhanced airway hyperresponsiveness after IFN-alpha treatment, although other pulmonary functions, including FEV1, showed no change between before and after treatment in any patients [30]. Another publication reported that the IFN response to chronic hepatitis C was associated with impaired responses to inhaled corticosteroid therapy in patients with both asthma and chronic hepatitis C, but no responders showed improved FEV1, by inhaled corticosteroid therapy [31]. Although IFN-alpha improves asthma in patients without chronic hepatitis C, we have to understand that IFN-alpha may cause exacerbation of asthma in patients with chronic hepatitis C.

In our study, low-dose IFN-alpha inhibited the expression of ICAM-1 but not VCAM-1. However, high-dose IFN-alpha inhibited expression of both ICAM-1 and VCAM-1. Several studies have reported that treatment of IFN-alpha decreased the serum levels of soluble ICAM-1, but not soluble VCAM-1, in patients with chronic hepatitis C [32, 33]. Such results suggest that the main target of adhesion molecules will be ICAM-1, which can be inhibited by low-dose IFN-alpha. ICAM-1 expression on human endothelial cells is enhanced by IL-1 beta and tumor necrosis factor [34]. IFN-alpha inhibits ICAM-1 expression, because IFN-alpha inhibits IL-1 induced by endothelial cells [35]. Accordingly, eosinophil migration into tissue is inhibited.

In our study, low-dose IFN-alpha inhibited the expression of ICAM-1 but not VCAM-1. However, high-dose IFN-alpha inhibited expression of both ICAM-1 and VCAM-1. Several studies have reported that treatment of IFN-alpha decreased the serum levels of soluble ICAM-1, but not soluble VCAM-1, in patients with chronic hepatitis C [32, 33]. Such results suggest that the main target of adhesion molecules will be ICAM-1, which can be inhibited by low-dose IFN-alpha. ICAM-1 expression on human endothelial cells is enhanced by IL-1 beta and tumor necrosis factor [34]. IFN-alpha inhibits ICAM-1 expression, because IFN-alpha inhibits IL-1 induced by endothelial cells [35]. Accordingly, eosinophil migration into tissue is inhibited.

In our study, the same results were shown both in vivo and in vitro, indicating that ICAM-1 may play an important role in airway eosinophilic inflammation. On the other hand, ICAM-1 expression is not always inhibited by IFN-alpha therapy. It was reported that 10 of 23 patients with metastatic malignant melanoma showed high expression of ICAM-1 after IFN-alpha therapy [36]. In addition, patients with metastatic malignant melanoma who developed depression had higher soluble ICAM-1 levels than non-depressed patients after treatment with IFN-alpha, compared with baseline levels [37]. IFN-alpha treatment may also contribute to neurotoxic effects. Furthermore, ICAM-1 expression in malignant diseases is
increased and other signaling pathways in malignant diseases will be constructed to be increased ICAM-1 expression by IFN-alpha treatment.

IFN-alpha dose-dependently reduced the number of infiltrating eosinophils in airway tissue in our study. Two processes are candidate mechanisms through which IFN-alpha inhibits airway eosinophilic inflammation. The first process is inhibition of eosinophils by IFN-alpha via downregulation of T helper type 2 (Th2) cells. Here, IFN-alpha and IL-12 jointly promote differentiation of T helper type 0 (Th0) toward the T helper type 1 (Th1) phenotype, and IFN-alpha selectively stimulates Th1 cells to release IFN-gamma [38-40]. The activated Th1 cells downregulate Th2 cells by Th1-Th2 balance and inhibit the release of cytokines, which in turn activates eosinophils and mast cells, such as IL-4 and IL-5, from Th2 cells. Airway eosinophilic inflammation is subsequently inhibited by downregulation of Th2 cells. The second process is inhibition of the migration of eosinophils into airway tissue by IFN-alpha via ICAM-1 on HUVECs. The expression of HUVEC surface ICAM-1 is induced by tumor necrosis factor-alpha (TNF-alpha) and IL-1 [41], and the expression of ICAM-1 stimulated by IL-1 was inhibited by IFN-alpha in our study. The experiment for signaling pathways has not been performed, and we cannot explain the reason. Because ICAM-1 expression in malignant diseases is increased by IFN-alpha treatment, signaling pathways may not be simple. But, in an animal model of asthma without malignant diseases, IFN-alpha inhibits the expression of ICAM-1 on HUVECs. Thus, it is thought that IFN-alpha inhibits airway eosinophilic inflammation via both of these two processes, leading to inhibition of airway hyperresponsiveness.

In conclusion, IFN-alpha inhibits airway eosinophilic inflammation and airway hyperresponsiveness possibly by inhibition of ICAM-1 expression on endothelial cells. IFN-alpha is used widely for patients with chronic hepatitis C and can be used safely. Therefore, IFN-alpha treatment should be considered for uncontrolled patients with glucocorticoid-dependent severe asthma. However, when patients have malignant diseases or chronic virus infections, such as chronic hepatitis C, caution must be taken when using IFN-alpha because pulmonary function or airway hyperresponsiveness may be decreased when coexisting with those diseases.

ACKNOWLEDGEMENTS

Authors thank Dr. Takashi Ueda, Dr. Yoshinori Terashi, and Dr. Hironori Sagara for technical advice and Dr. Cheng Gang for technical assistant. In addition, we thank Miss Ayano Takeda for her assistance preparing the manuscript.

REFERENCES

1. Barnes PJ. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J Allergy Clin Immunol 1989;83:1013-26.
2. Bousquet J, Chanez P, Lacoste JY, Barnèon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, Michel FB. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-9.
3. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988;167:219-24.
4. Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989;19:701-5.
5. Fukuda T, Nakajima H, Fukushima Y, Akutsu I, Numao T, Majima K, Motojima S, Sato Y, Takatsu K, Makino S. Detection of interleukin-5 messenger RNA and interleukin-5 protein in bronchial biopsies from asthma by nonradioactive in situ hybridization and immunohistochemistry. J Allergy Clin Immunol 1994;94:584-93.
6. Adachi T, Motojima S, Hirata A, Fukuda T, Makino S. Eosinophil viability-enhancing activity in sputum from patients with bronchial asthma, Contributions of interleukin-5 and granulocyte/macrophage colony-stimulating factor. Am J Respir Crit Care Med 1995;151:618-23.
7. Sur S, Kita H, Gleich GJ, Chenier TC, Hunt LW. Eosinophil recruitment is associated with IL-5, but not with RANTES, twenty-four hours after allergen challenge. J Allergy Clin Immunol 1996;97:1272-8.
8. Sanmugalingham D, De Vries E, Gauntlett R, Symon FA, Bradding P, Wardlaw AJ. Interleukin-5 enhances eosinophil adhesion to bronchial epithelial cells. Clin Exp Allergy 2000;30:255-63.
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçalves FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
11. Poordad F, McConne J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
12. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Fisiak R, George KR, Bzowej NH, Marcellin P, Muir AJ, Fisiak R, George
IFN-α inhibits airway hyperresponsiveness

J. Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.

Shibuya H, Hirohata S. Differential effects of IFN-alpha on the expression of various TH2 cytokines in human CD4+ T cells. J Allergy Clin Immunol 2005;116:205-12.

Tigl H, Kaser A. Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders. Expert Opin Biol Ther 2004;4:469-81.

Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999;54:825-57.

Schandén L, Del Prete GF, Cogan E, Stordeur P, Crsiaux A, Kennes B, Romagnani S, Goldman M. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest 1996;97:309-15.

Nakajima H, Nakao A, Watanabe Y, Yoshida S, Iwamoto I. IFN-alpha inhibits antigen-induced eosinophil and CD4+ T cell recruitment into tissue. J Immunol 1994;153:1264-70.

Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998;129:370-4.

Termeer CC, Simon JC, Schöpf E. Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with skin involvement. Arch Dermatol 2001;137:136-8.

Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004;5:25-35.

Cheng G, Udeta T, Sugiyama K, Toda M, Fukuda T. Compositional and functional changes of pulmonary surfactant in a guinea-pig model of chronic asthma. Respir Med 2001;95:180-6.

Mead J. Control of respiratory frequency. J Appl Physiol 1960;15:325-36.

Toda M, Motojiima S, Fukuda T, Makino S. Effect of an herbal preparation, Saiboku-to (TJ-96), on antigen-induced airway hyperresponsiveness and eosinophil infiltration in actively sensitized guinea pigs. Ann NY Acad Sci 1993;685:561-71.

Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118:1727-35.

Ebisawa M, Bochner BS, Georas SN, Schleimer RP. Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. J Immunol 1992;149:4021-8.

Gratzl S, Palca A, Schmitz M, Simon HU. Treatment with IFN-alpha in corticosteroid-unresponsive asthma. J Allergy Clin Immunol 2000;105:1035-6.

Simon HU, Seelbach H, Ehmann R, Schmitz M. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy 2003;58:1250-5.

Kroegel C, Bergmann N, Foerster M, Workalemahu G, Machnik A, Mock B, Reissig A. Interferon-alphacon-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose. Respiration 2006;73:566-70.

Bini EJ, Weinshel EH. Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C. Mayo Clin Proc 1994;79:367-70.

Shirai T, Honjo Y, Takashima M, Takayanagi S, Chida K, Nakamura H. Effect of interferon-α on pulmonary function and airway responsiveness in patients with chronic hepatitis C. Allergol Int 2001;50:331-5.

Kanazawa H, Mamoto T, Hirata K, Yoshikawa J. Interferon therapy induces the improvement of lung function by inhaled corticosteroid therapy in asthmatic patients with chronic hepatitis C virus infection: a preliminary study. Chest 2003;123:600-3.

Capra F, De Maria E, Lunardi C, Marchiori L, Mezzelani P, Beri R, Gabrielli GB. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: A prognostic marker for responses to interferon treatment. J Infect Dis 2000;181:425-31.

Dejica D, Grigorescu M, Dejica V, Radu C, Neculoiu D. Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-alpha + ribavirin therapy. Rom J Gastroenterol 2002;11:277-83.

Pober JS, Gimbrone MA Jr, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 1986;137:1893-6.

Schindler R, Ghezzi P, Dinarello CA. Interferons as inhibitors of interleukin 1 induced interleukin 1 synthesis. Lymphokine Res 1989;8:275-80.

Håkansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Håkansson L. Expression of ICAM-1 during IFN-alpha-based treatment of metastatic malignant melanoma: relation to tumor-infiltrating mononuclear cells and regressive tumor changes. J Interferon Cytokine Res 1990;19:171-7.

Schafer M, Horn M, Schmidt F, Schmid-Wendtner MH, Volkenandt M, Ackenheil M, Mueller N, Schwarz MJ. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav Immun 2004;18:555-62.

Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.

Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-3.

Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.

Bochner BS, Luscinskas FW, Gimbrone MA Jr, Newman W, Sterbinsky SA, Derse-Anthony CP, Klunk D, Schleimer RP. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 1991;173:1553-7.